Corbus Pharmaceuticals (CRBP) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRBP:
- Corbus Pharmaceuticals initiated with an Overweight at Piper Sandler
- Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
- Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- Corbus Pharmaceuticals Reports Q3 2024 Financial Results
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
